What it's for (Indications)
- Methyldopa, often marketed under brand names such as Hypergen, is an antihypertensive agent primarily indicated for the management of hypertension, ranging from mild to severe.
- Its clinical utility is particularly prominent in specific patient populations.
- It is a well-established and frequently considered therapeutic option for controlling high blood pressure during pregnancy (gestational hypertension, pre-eclampsia, and chronic hypertension in pregnancy) due to its extensive history of use and documented safety profile for both mother and fetus, making it one of the preferred first-line agents in this context.
- While not typically a first-line treatment for essential hypertension in non-pregnant adults due to the availability of newer agents with more favorable side effect profiles, methyldopa may be utilized when other antihypertensive medications are contraindicated, poorly tolerated, or ineffective.
- Its application ensures blood pressure control, which is crucial in preventing serious cardiovascular, cerebrovascular, and renal complications associated with uncontrolled hypertension.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | * Adults - Initiation of Therapy: The usual starting dosage is 250 mg two to three times a day for the first 48 hours. * Dosage Adjustment: The daily dosage may be increased or decreased, preferably at intervals of not less than 2 days, until an adequate response is achieved. To minimize sedation, consider starting dosage increases in the evening. * Maintenance of Therapy: The usual daily dosage of methyldopa tablets is 500 mg to 2 g, administered in divided doses. * Concurrent Antihypertensive Therapy: When methyldopa is given to patients on other antihypertensives, the dose of these agents may need adjustment. If methyldopa is given with antihypertensives other than thiazides, the initial dosage of methyldopa should be limited to 500 mg daily in divided doses. When methyldopa is added to a thiazide, the dosage of the thiazide typically need not be changed. |
Safety & Warnings
Common Side Effects
- Commonly reported or transient effects include sedation (especially at therapy initiation or dose increase), headache, asthenia, and weakness.
- More significant adverse reactions, though infrequent, can affect various systems: * Cardiovascular: Aggravation of angina pectoris, congestive heart failure, prolonged carotid sinus hypersensitivity, orthostatic hypotension, edema or weight gain, bradycardia.
- * Digestive: Pancreatitis, colitis, vomiting, diarrhea, sialadenitis, sore or 'black' tongue, nausea, constipation, distension, flatus, dryness of mouth.
- * Endocrine: Hyperprolactinemia.
- * Hematologic: Bone marrow depression, leukopenia, granulocytopenia, thrombocytopenia, hemolytic anemia; positive tests for antinuclear antibody, LE cells, and rheumatoid factor.
- Patients should consult a doctor if symptoms persist or are severe.
Serious Warnings
- Black Box Warning: None provided in the available data.
- * Pregnancy: This medication can be used during pregnancy.
- * Lactation: Consult a doctor before using this medication when lactating.
- * Driving & Alcohol: Please avoid driving and consuming alcohol when taking this medicine, as it may affect your ability to drive and increase sedation risk.
- * Medical Conditions: This medicine should be used with extreme caution in patients with hemolytic anemia (blood disorder with decreased red blood cells) or those with a history of liver disorder.
- Close monitoring of liver function and hematologic parameters is recommended.
How it Works (Mechanism of Action)
Methyldopa functions as a centrally acting sympatholytic agent. It is a prodrug that requires metabolic activation in the central nervous system (CNS). Specifically, methyldopa is taken up into adrenergic neurons in the CNS, where it is decarboxylated by L-aromatic amino acid decarboxylase to alpha-methyldopamine and subsequently hydroxylated by dopamine beta-hydroxylase to form alpha-methylnorepinephrine. This alpha-methylnorepinephrine acts as a false neurotransmitter that preferentially stimulates central alpha-2 adrenergic receptors. Activation of these presynaptic alpha-2 receptors in the brainstem leads to a reduction in sympathetic outflow from the CNS to the peripheral cardiovascular system. The net physiological effect is a decrease in peripheral vascular resistance, heart rate, and cardiac output, which collectively results in a reduction in both systolic and diastolic blood pressure. Unlike peripheral alpha-2 agonists, methyldopa's hypotensive effect is predominantly mediated by its central actions, differentiating its pharmacokinetic and pharmacodynamic profile.